Bioanalytical testing considerations

Gene therapy developers must establish a robust bioanalytical testing strategy to support regulatory confidence in product safety and efficacy. Bioanalytical assays provide crucial evidence that a gene therapy reaches target tissues, expresses the intended transgene, and does so safely, without triggering unmanageable immune responses. This section outlines five core bioanalytical domains: Immunogenicity, Pharmacodynamics, Biodistribution, Viral Shedding, and Molecular Pathology. Here, BGTC offers a framework for deciding which assays to consider at various stages of development.

What is bioanalytical testing and why is it important?

In the context of drug development, bioanalytical testing refers to the quantitative measurement of drugs, biomarkers, and their metabolites in biological matrices (e.g. blood, plasma, tissue) using analytical laboratory methods [1]. It helps answer critical questions that regulators ask during the IND process, such as:

• Is the therapy triggering any harmful immune responses?

• Is the transgene product biologically active in the patient?

• Did the vector reach its intended target tissue?

• Are there safety signals (like unexpected distribution or shedding of the virus) that need monitoring?

Addressing these questions with robust data is essential to demonstrate a favorable risk-benefit profile to proceed through regulatory milestones.

Key Domains of Bioanalytical Strategy for AAV Gene Therapies

While this playbook covers five major domains, there may be additional testing required based on your gene therapy and disease indication. We describe each domain below, including what is measured, why it matters, common methodologies, and regulatory considerations. It is important to note that the need for each type of assay should be carefully justified based on the product and trial context.

1. Immunogenicity Assays

What & Why: Immunogenicity assays measure immune responses triggered by the gene therapy. Primarily, the body’s immune recognition of the AAV vector capsid and/or the transgene product. This is a crucial domain because immune responses can impact both safety and efficacy. Regulators are interested in proof that patients were appropriately screened (to avoid non-eligible patients) as well as planned to be continuously monitored throughout the clinical trial [2]. For AAV therapies, two main immunogenic components are considered: (a) the AAV vector capsid and (b) the transgene-encoded protein. The transgene could be seen as foreign by the patient’s immune system, especially if the patient’s disease is caused by a total absence of that protein. Two types of immunogenicity assays are humoral (Nab/TAb/ADA) and cellular (T-cell).

From a CMC regulatory perspective, immunogenicity is tied to product and process understanding because product related attributes such as capsid composition, impurities, genome design can influence immune risk. That means regulators expect a developer to show how manufacturing and analytical controls help manage features that may increase immunogenicity and affect product consistency across lots.

Common Assays and Approaches

• Neutralizing Antibody (NAb) Assays: These are cell-based assays that detect antibodies capable of neutralizing the AAV vector’s ability to infect cells (deliver that gene therapy). They are typically reported as a titer (the highest serum dilution that inhibits a certain percentage of transduction in vitro). Anti-AAV antibody assays are useful for baseline screening of patients: AAV clinical trials may exclude patients with high titers of anti-AAV neutralizing antibodies, since those antibodies can drastically reduce gene therapy efficacy. Sponsors may use literature or prior study data to select a cutoff, but since population immunity to common AAV serotypes (like AAV2, AAV8, AAV9, etc.) can be significant, this assay is helpful for Phase 1 trials as an eligibility criterion [3]. Post-dose, patients are expected to develop high-titer anti-capsid antibodies, so routine monitoring of anti-capsid antibodies after dosing is generally of limited utility (it is an expected outcome that confirms exposure), but may still be expected of sponsors [2].

BGTC Learning

Sponsors should also consider route of administration when developing screening criteria. BGTC programs using intrathecal delivery did not exclude based on antibodies, since CSF antibody levels tend to be low. Yet, this may not be the case for every AAV program delivering intrathecally, and immunogenicity assay approaches should be confirmed with the FDA.

Sponsors should also recognize that each laboratory applies its own standard for what counts as a positive result, and that ELISA titers are not directly translatable across labs. It is therefore essential to confirm the reference lab's positivity criteria up front and to apply that same standard consistently throughout the program.

• Total Antibody (TAb) Assays: TAb assays are ligand-binding assays (e.g., ELISA-based) that detect both neutralizing and non-neutralizing antibodies binding to the AAV capsid. Sponsors weighing NAb vs. TAb screening should consider that non-neutralizing antibodies are not biologically inert. They can still reduce circulating vector so a TAb-based screen also captures the full population of patients at risk of reduced transduction. Sponsors should also pre-specify which immunoglobulin classes (IgG, IgA, IgM, or a combination) the TAb assay is designed to detect, as this directly affects interpretation of exclusion thresholds. Yet, because it is not currently established whether neutralizing or total binding antibodies are more informative, the FDA does not favor a specific approach.

• Anti-Transgene Antibodies: These are usually measured by bridging ELISA or similar immunoassays to detect antibodies against the therapeutic protein that the gene therapy produces. It is most relevant when the transgene encodes a secreted or extracellular protein (e.g. a blood enzyme, hormone, or clotting factor) that the immune system can encounter. If the patient’s immune system has never been exposed to a certain version of that protein, the risk of developing anti-transgene antibodies is higher. The FDA expects sponsors to evaluate this risk; in many cases, anti-transgene antibodies are assessed in clinical trials as part of the safety profile [2].

• T-cell Response Assays (e.g., ELISpot assays): T-cell mediated immunity can target either the AAV capsid or the transgene-expressing cells. An ELISpot assay can detect T cells producing cytokines in response to peptides from the capsid or transgene protein. Importantly, regulators do not presently mandate T-cell assays as a requirement for initial trials because results are not typically used to make near-term clinical decisions, given the assays are retrospective and not standardized for clinical practice [2]. In practice, the use of T-cell assays in Phase 1 is often to collect data that might explain adverse events. FDA’s focus is on patient safety: if sponsors have a reason to suspect T-cell reactions could cause a safety risk, they may expect a risk mitigation plan rather than solely an ELISpot monitoring plan. Thus, for Phase 1/2, many teams may collect and store samples for T-cell assays but not necessarily execute the assays in real-time [3]. Sponsors can propose a targeted approach and should discuss this at pre-IND meetings.

• Flow Cytometry for Cytokine Production: Flow cytometry–based intracellular cytokine staining (ICS), measures T‑cell cytokine production at the single‑cell level. Cells are stimulated with antigen (e.g., capsid or transgene peptides), and a protein transport inhibitor is used to trap cytokines intracellularly. Cells are then fixed, permeabilized, and stained with fluorescent anti‑cytokine antibodies, enabling flow cytometry to quantify which cells are producing cytokines and their phenotype (e.g., CD4⁺/CD8⁺). Flow cytometry provides multiparametric data, allowing assessment of cell type, frequency, and polyfunctionality of cytokine-producing T cells. These assays are generally used in preclinical or exploratory clinical settings to better understand immune responses or interpret safety signals [8].

2. Pharmacodynamics (PD) / Transgene Product Assays

What & Why: For gene therapies PD mainly refers to measuring the transgene’s product or its direct biological effect. Essentially, these assays answer: Did the introduced gene lead to production of the intended therapeutic molecule in the patient, and is it biologically active? For many gene therapies, the product protein’s level or activity is measured in blood or tissue. For others, PD may be inferred through surrogate biomarkers or functional assays rather than direct measurement of the protein. Regulatory guidance emphasizes the importance of confirming your gene therapy’s biological activity in humans as early as possible, especially in efficacy trials; even in Phase 1, sponsors should explore PD endpoints as they can provide proof-of-concept that the vector is working as intended [2].

Common Assays and Approaches

• Transgene Protein Quantification: For gene therapies that produce a secreted transgene protein, the protein can be measured directly in accessible biofluids such as blood, plasma, or serum. For therapies targeting the central nervous system (CNS), the protein may instead be quantified in cerebrospinal fluid (CSF) if secretion occurs there. Common analytical approaches include enzyme activity assays (for enzymatic transgenes), ELISA (for protein concentration), and functional assays, such as flow‑cytometry–based readouts, for hormones or signaling molecules.

• Surrogate Biomarkers: If the transgene’s product cannot be easily measured, sponsors may want to identify downstream effects or markers that can be measured. For instance, for a metabolic disorder gene therapy, one might track metabolite levels in blood or urine that the target enzyme normally regulates. For more on surrogate biomarkers, explore the Statistical considerations for rare disease trial design.

• Molecular assays for gene expression: Another way to confirm that the gene therapy is active is to measure vector-derived mRNA in tissue samples (e.g. via reverse transcription quantitative polymerase chain reaction/ RT-qPCR) or to use reporter gene expression if applicable. However, in patients it can be difficult or unethical to get tissue biopsies; this is more common in animal studies. In clinical trials, occasionally sponsors might take a tissue biopsy (say, a muscle biopsy in a muscular dystrophy gene therapy) to directly measure the protein or mRNA. In most AAV trials for rare diseases, invasive biopsies are minimized unless critical. Therefore, reliance is on fluid-based markers or imaging if available (for example, if the gene therapy is supposed to express a hormone, measuring that hormone in serum would be the PD evidence).

3. Biodistribution Studies

What & Why: Biodistribution (BD) studies determine where the vector (and/or transgene) travels and persists in the body. It ties directly to safety as a vector found in unintended sites at high levels could cause toxicity. Additional risks could occur if vectors enter reproductive cells there is a theoretical risk of transmission to newborns [4]. These biodistribution studies inform dosing and dose scheduling by informing how long vector genomes persist in the body. For AAV gene therapies, biodistribution is typically first characterized in animal models as part of IND-enabling toxicology studies. In most cases, regulators expect a thorough BD assessment in animals to support trial initiation. This means measuring vector genome levels in a wide panel of tissues (e.g., via qPCR for vector DNA) after administration, to confirm that there is no unexpected accumulation in off-target organs that might raise safety or environmental concerns. In humans, comprehensive BD data is hard to obtain since multiple organ biopsies are impractical and unethical. However, certain data may be collected if feasible: for instance, analysis of vector DNA in blood or saliva over time as an indicator of how the vector disseminates or clears.

CMC aspects are deeply intertwined with the in vivo behavior of AAV gene therapies. Decisions made during vector design, upstream production, downstream processing and final formulation dictate the products physical and biochemical properties.

Key considerations include:

1. Capsid post translational modifications

2. Transduction efficiency

3. Empty & Partial Capsids

4. Residual Impurities

5. Formulation Factors (pH, ionic strengths, excipients)

Regulators expect CMC programs to tightly control these variables [6][7].

Common Assays and Approaches

• qPCR for Vector Genomes (DNA): A common assay for BD is a quantitative polymerase chain reaction targeting a unique sequence of the vector (often the transgene’s polyA signal or promoter sequence, which wouldn’t appear in normal human DNA). Sponsors perform qPCR on DNA extracted from tissue samples. In preclinical GLP studies, a large panel of tissues is analyzed at multiple time points. The FDA emphasizes the need for tissue distribution data for gene therapies. In clinical trials, biodistribution in humans is typically limited: one might assay peripheral blood for vector DNA, or assay possible target tissues if accessible. However, routine multi-organ BD in trial participants is not expected; instead regulators will look at the animal data and any clinical surrogate (like blood PCR) to infer distribution [4]. If prior literature or “platform” data exist for the same capsid and route, sponsors may be able to leverage that information, but this must be confirmed with the FDA.

• qPCR for Transgene RNA: A common approach to assess transgene RNA expression is quantitative reverse transcription PCR (qRT‑PCR) targeting a vector‑specific transcript sequence (e.g., coding region or engineered UTR elements not present endogenously). Sponsors perform qRT‑PCR on RNA from tissue samples, typically analyzing a panel of tissues across multiple time points in preclinical studies to characterize expression [9].

• RNA ISH for Transgene RNA: As a complementary approach, RNA in situ hybridization (RNA ISH) can be used to detect transgene RNA directly within tissue sections using labeled probes targeting the transcript. This method enables spatial and single‑cell localization of transgene expression within intact tissue architecture, helping to identify which cell types are expressing the transcript, particularly in heterogeneous or safety‑relevant tissues [9].

• IHC for Transgene protein: A common method to assess transgene protein expression is immunohistochemistry (IHC), which uses antibodies specific to the expressed protein to visualize its presence in tissue. Sponsors apply IHC across multiple tissues and time points in preclinical studies to evaluate distribution, persistence, and off‑target expression [3].

• IF for Transgene protein: Immunofluorescence (IF) is often used as a complementary approach, employing fluorophore‑labeled antibodies to detect transgene protein with higher resolution. IF enables more precise identification of which cells express the protein within a given tissue [3]. Biodistribution vs. Shedding: It’s worth clarifying that biodistribution refers to within the treated subject’s body, whereas shedding (next section) refers to release from the body. The FDA’s guidance clearly distinguishes the two. BD data ensures the vector isn’t accumulating unexpectedly inside the body, while shedding data addresses environmental transmission [5].

4. Viral Shedding Studies

What & Why: Shedding studies investigate whether the vector (or related genetic material) is released from the treated individual’s body into the environment. While related to biodistribution, shedding is about excretion. It addresses questions like: Could the AAV vector be present in a patient’s blood or other bodily fluids? How long does such shedding last post-treatment? In the U.S., the FDA’s focus on shedding assesses risk of transmission to untreated individuals and any implications for requiring containment [5].

Common Assays and Approaches

• Quantitative PCR (qPCR) for Vector Genomes in Excreta: Similar to biodistribution, qPCR is used to detect vector DNA in samples like patient urine, stool, saliva, nasopharyngeal swabs, semen, etc. The assay should be qualified to ensure lack of interference from each of the sample matrices, since these are very different sample types. The sensitivity needs to be high since shedding, if it occurs, is often at low levels. Typically, shedding studies might involve collecting such specimens at regular intervals post-dose (e.g., weekly for first month, then monthly) to see when/if the vector DNA falls below detection. Results are reported as genome copies per mL (or per gram for feces). If PCR shows very low levels that drop over time, a case may be made that risk of infectious virus shedding is negligible.

  • Shedding in Preclinical Studies: FDA guidance notes that animal shedding data can help design human shedding studies but cannot replace them entirely. If a vector sheds in animals (e.g., found in animal feces), it suggests it might in humans. However, differences in size and metabolism mean animal data are just supportive. Most IND packages for AAV will include at least a statement on shedding observed in animal studies (often, vector DNA is transiently found in animal urine/feces after high IV doses, but generally not beyond a few weeks) [5]. Analysis of shedding is usually done in toxicology or biodistribution studies.

5. Molecular Pathology (IHC/ISH) Analyses

What & Why: Molecular pathology techniques like Immunohistochemistry (IHC) and In Situ Hybridization (ISH) are used to detect the presence of the transgene protein or vector genetic material in tissue sections, respectively. These techniques are useful when qPCR is not possible (e.g. target tissue is in the eye) [3]. In clinical trials, IHC/ISH are rarely performed except possibly on biopsies or explanted tissues (for example, if a patient undergoes a biopsy). In the context of your bioanalytical strategy, these methods are often deployed in animal studies to get a qualitative, spatial understanding of gene therapy distribution and expression in tissues. For example, IHC can reveal which cells in the liver are expressing the transgene protein, or ISH can show whether vector DNA is in neurons vs. other cells in the brain. If gene expression needs to be in, say, specific cell layers of the retina and not elsewhere, these techniques are important.

Case-by-Case Use in Development: Some scenarios where molecular pathology is particularly useful include:

• Ocular Gene Therapies: For AAV treatments of the eye, it might be critical to know if transgene expression is occurring in certain retinal layers. IHC on retinal sections from animal models can demonstrate expression pattern.

• Histopathology for Safety: Sometimes, if unexpected tissue changes are observed (e.g. inflammation), doing IHC for immune cell markers (like CD8 T-cells) or the transgene protein can help determine if the transgene expression is co-localizing.

• Fallback when PCR is not feasible: As mentioned, in small organs or unique cases, taking a tissue for PCR might destroy the tissue. Instead, sponsors might propose analyzing tissues via ISH/IHC to glean distribution [3].

Bioanalytical Assay Overview

*Rare clinical biopsy